DNA Biomed Solns Cash Flow Quality Index
DNA Biomed Solns cash flow quality index. DNA Biomed Solns (DNA) has a Cash Flow Quality Index of -0.21x as of June 2023. Operating cash flow of ILA-265.00K is below net income of ILA1.27 Million, suggesting accrual-heavy earnings not yet converted to cash. See DNA financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of DNA Biomed Solns (2017–2024)
Cash flow quality index of DNA Biomed Solns from 2017 to 2024. Historical Cash Flow Quality Index for DNA Biomed Solns across 3 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore DNA Biomed Solns cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
DNA Biomed Solns Cash Flow Quality Index by Year (2017–2024)
DNA Biomed Solns cash flow quality index by year from 2017 to 2024. Year-by-year earnings quality comparison for DNA Biomed Solns. For the full cash flow conversion analysis, see how efficiently does DNA Biomed Solns generate cash.
| Year | Quality Index | Operating CF (ILA) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 0.07x | ILA1.61 Million | ILA22.10 Million | ▲ +157.4% |
| 2021 | -0.13x | ILA-2.33 Million | ILA18.37 Million | ▼ -881.3% |
| 2017 | -0.01x | ILA-1.91 Million | ILA147.36 Million | — |